- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00887822
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer (AVATAR)
10. ledna 2017 aktualizováno: Hoffmann-La Roche
A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer.
Participants will be randomized to one of two treatment groups Bevacizumab + Capecitabine/Cisplatin (experimental arm) or Placebo + Capecitabine/Cisplatin (control arm).
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Aktuální)
202
Fáze
- Fáze 3
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
-
Beijing, Čína, 100021
-
Beijing, Čína, 100142
-
Beijing, Čína, 100071
-
Beijing, Čína, 100853
-
ChongQing, Čína, 400042
-
Guangzhou, Čína, 510060
-
Hangzhou, Čína, 310016
-
Nanjing, Čína
-
Nanjing, Čína, 210036
-
Shanghai, Čína, 200032
-
Shanghai, Čína, 200080
-
Shantou, Čína, 515041
-
Shenyang, Čína, 110001
-
Wuhan, Čína, 430030
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let a starší (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable, locally advanced or metastatic disease, not amenable to curative therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
- Measurable disease or non-measurable but evaluable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Exclusion Criteria:
- Previous chemotherapy for locally advanced or metastatic gastric cancer
- Previous platinum or anti-angiogenic therapy
- Radiotherapy within 28 days of randomization
- Evidence of Central Nervous System (CNS) metastasis at baseline
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Bevacizumab, Capecitabine and Cisplatin
Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
|
7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
Ostatní jména:
1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
Ostatní jména:
80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
|
|
Komparátor placeba: Placebo, Capecitabine and Cisplatin
Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
|
1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
Ostatní jména:
80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
Placebo matched to bevacizumab on Day 1 of every 3-week cycle
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants With Event (Death)
Časové okno: From randomization until death (up to 34 months)
|
Percentage of participants who died due to any cause was reported.
As planned, ad hoc analysis was done for overall survival up to clinical cut-off date of 12 January 2012 (34 months), subsequent to the protocol-defined clinical cut-off date of 13 May 2011 (26 months).
Overall survival was defined as the time between randomization and the date of death due to any cause.
|
From randomization until death (up to 34 months)
|
|
Overall Survival
Časové okno: From randomization until death (up to 34 months)
|
Overall survival was defined as the time between randomization and the date of death due to any cause.
Overall survival was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive.
As planned, ad hoc analysis was done for overall survival up to clinical clinical cut-off date of 12 January 2012 (34 months), subsequent to the protocol-defined clinical cut-off date of 13 May 2011 (26 months).
|
From randomization until death (up to 34 months)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants With Progression-Free Survival (PFS) Events (Disease Progression/Death)
Časové okno: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20 percent (%) increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 millimeters (mm), progression of existing non-target lesions, or presence of new lesions.
PFS was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first, according to Response Evaluation Criteria In Solid Tumors (RECIST).
|
From randomization until disease progression or death (up to 26 months)
|
|
Progression-Free Survival (PFS)
Časové okno: From randomization until disease progression or death (up to 26 months)
|
PFS was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first, according to RECIST.
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who had neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow-up for progression of disease.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With PFS Events (Disease Progression/Death) During First-line Therapy
Časové okno: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS during first-line therapy was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first and only if it occurred no later than 28 days after last confirmed intake of any study medication and before the start of non-study antineoplastic treatment, according to RECIST.
|
From randomization until disease progression or death (up to 26 months)
|
|
PFS During First-line Therapy
Časové okno: From randomization until disease progression or death (up to 26 months)
|
PFS during first-line therapy was defined as time between randomization and date of first documented disease progression or death, whichever occurred first and only if it occurred no later than 28 days after last intake of any study medication and only if it occurred before start of non-study antineoplastic treatment, according to RECIST.
Progression of disease was defined as at least 20% increase in sum of longest diameters of target lesions compared to smallest sum of longest diameters on-study & absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who neither progressed nor died in this interval, or who were lost to follow-up were censored at date of last tumor assessment/last follow-up within this time window.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Disease Progression
Časové okno: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
|
From randomization until disease progression or death (up to 26 months)
|
|
Time to Progression
Časové okno: From randomization until disease progression or death (up to 26 months)
|
Time to progression was defined as the time between randomization and the first occurrence of disease progression.
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Time to progression was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who had not progressed at the time of study completion (including participants who had died before disease progression) or who were lost to follow-up were censored at the date of the last tumor assessment or last follow-up for progression of disease.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Best Overall Response as Assessed by RECIST During First-Line Therapy
Časové okno: From randomization until disease progression or death (up to 26 months)
|
Best overall response during first-line therapy was defined as the occurrence of either a confirmed complete (CR) or a partial response (PR), as assessed by the RECIST criteria.
CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers.
Pathological lymph nodes must have short axis measures less than (<) 10 mm.
PR: at least a 30 % decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of longest diameters.
|
From randomization until disease progression or death (up to 26 months)
|
|
Duration of Response During First-Line Therapy
Časové okno: From randomization until disease progression or death (up to 26 months)
|
Duration of response during first-line therapy was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first-line therapy.
CR: disappearance of all target and non-TLs and normalization of tumor markers.
Pathological lymph nodes must have short axis measures <10 mm.
PR: at least a 30 % decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of longest diameters.
Duration of response was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who did not progress or die after they had had a confirmed response were censored at the date of their last tumor measurement or last follow-up for progression of disease during first line therapy.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Disease Control During First-Line Therapy
Časové okno: From randomization until disease progression or death (up to 26 months)
|
Disease control was defined as stable disease(SD) for 6 weeks or longer, CR plus PR as assessed by RECIST criteria for participants with measurable disease.CR:disappearance of all TLs & normalization of tumor markers.
Pathological lymph nodes must have short axis measures<10 mm.
PR:at least 30% decrease in sum of measures(longest diameter for tumor lesions and short axis measure for nodes)of TLs, taking as reference baseline sum of longest diameters.SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression taking as reference smallest sum of longest diameters on study.
For participants without measurable disease, clinical benefit rate was defined as no clinical disease progression for >/=6 weeks.
Disease progression was defined as at least 20% increase in sum of diameters of TLs compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
|
From randomization until disease progression or death (up to 26 months)
|
|
Change From Cycle 1 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 36 (QLQ-C30) Scale Over Time
Časové okno: From Cycle 1 until disease progression (up to 26 months)
|
EORTC QLQ-C30 included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties).
Most questions used a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used a 7-point scale (1 'Very Poor' to 7 'Excellent').
Scores were averaged and transformed to 0-100 scale; a higher score for Global Qol/functional scales=better level of QoL/functioning, or a higher score for symptom scale=greater degree of symptoms.
|
From Cycle 1 until disease progression (up to 26 months)
|
|
Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time
Časové okno: From Cycle 1 until disease progression (up to 26 months)
|
The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire.
There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image).
Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer).
A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
|
From Cycle 1 until disease progression (up to 26 months)
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. března 2009
Primární dokončení (Aktuální)
1. května 2011
Dokončení studie (Aktuální)
1. srpna 2014
Termíny zápisu do studia
První předloženo
22. dubna 2009
První předloženo, které splnilo kritéria kontroly kvality
23. dubna 2009
První zveřejněno (Odhad)
24. dubna 2009
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
1. března 2017
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
10. ledna 2017
Naposledy ověřeno
1. ledna 2017
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Nemoci trávicího systému
- Novotvary
- Novotvary podle místa
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Gastrointestinální onemocnění
- Onemocnění žaludku
- Novotvary žaludku
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Antimetabolity, Antineoplastika
- Antimetabolity
- Antineoplastická činidla
- Antineoplastická činidla, Imunologická
- Inhibitory angiogeneze
- Činidla modulující angiogenezi
- Růstové látky
- Inhibitory růstu
- Cisplatina
- Kapecitabin
- Bevacizumab
Další identifikační čísla studie
- ML22367
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .